Karus's earliest programmes centred on the development of highly-potent pan-HDAC inhibitors for the treatment of cancer and inflammatory disease. Building on the success of these early programmes, Karus has developed a pipeline of innovative drug candidates with significant clinical and commercial potential in the treatment of a wide range of chronic diseases such as rheumatoid arthritis, psoriasis and cancer.
The company operates an outsourced business model: retaining core research in-house whilst outsourcing a significant proportion of its R&D activities to a network of internationally recognised CROs. This approach has allowed Karus to remain capital efficient and flexible whilst advancing multiple R&D programmes through key value inflection points.
Originally funded by IP Group and the Sulis (now Wyvern) Fund, Karus's shareholder base includes investment funds based in the UK, mainland Europe and the United States. These funds are complemented by a number of Angel investors who have remained committed to Karus's growth and success.
The company's management team and board bring many man-decades experience of the biotechnology and pharmaceutical industries, including the successful design, development and commercialisation of a number of drug programmes.
Karus's business strategy is to develop its innovative drug candidates before securing exclusive partnering agreements with leading pharmaceutical companies.
Karus Therapeutics Ltd
2 Venture Road
Southampton Science Park
Chilworth
Hampshire
SO16 7NP
United Kingdom